Switzerland restricts reimbursement of orphan drugs

30 October 2023 - New rules for the reimbursement of orphan drugs and other unlisted medicines will become effective in Switzerland ...

Read more →

Santhera receives European marketing authorisation for Raxone in Leber's hereditary optic neuropathy (LHON)

9 September 2015 - Santhera Pharmaceuticals announces the European Commission (EC) has granted marketing authorisation for Raxone as the first approved ...

Read more →

European Commission grants marketing authorisation for Strensiq (asfotase alfa) for the treatment of patients with paediatric-onset hypophosphatasia (HPP)

1 September 2015 - Alexion Pharmaceuticals, Inc. announced today that the European Commission has approved Strensiq (asfotase alfa) for long-term enzyme ...

Read more →

European Commission grants marketing authorisation for Kanuma (sebelipase alfa) for the treatment of patients of all ages with lysosomal acid lipase deficiency (LAL-D)

1 September 2015 - Alexion Pharmaceuticals, Inc. announced today that the European Commission (EC) has approved Kanuma (sebelipase alfa) for long-term ...

Read more →